



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 333/52, 333/64, 207/04, 409/00, 405/00, A61K 31/38, 31/40, 31/445, 31/55		A1	(11) International Publication Number: WO 99/07693
			(43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16327 (22) International Filing Date: 6 August 1998 (06.08.98) (30) Priority Data: 60/055,472 11 August 1997 (11.08.97) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indi- anapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BRYANT, Henry, Uhlman [US/US]; 7840 Camelback Drive, Indianapolis, IN 46250 (US). DODGE, Jeffrey, Alan [US/US]; 11134 Indian Lake Boulevard, Indianapolis, IN 46236 (US). (74) Agents: SALES, James, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: BENZOTHIOPHENES			
<div style="text-align: center;"> <p>(I)</p> </div>			
(57) Abstract			
<p>This invention provides novel benzothiophene compounds of formula (I), which are useful for the treatment of the various medical conditions associated with postmenopausal syndrome, as well as estrogen dependent diseases including cancer of the breast, uterus, and cervix. The present invention further relates to pharmaceutical formulations of compounds of formula (I).</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

BENZOTHIOPHENES**Field of Invention**

5 This invention relates to the fields of pharmaceutical and organic chemistry and provides novel benzothiophene compounds which are useful for the treatment of the various medical conditions associated with postmenopausal syndrome, as well as estrogen-dependent diseases including cancer of
10 the breast, uterus, and cervix.

Background of the Invention

 "Postmenopausal syndrome" is a term used to describe various pathological conditions which frequently affect
15 women who have entered into or completed the physiological metamorphosis known as menopause. Although numerous pathologies are contemplated by the use of this term, three major medical conditions of postmenopausal syndrome are the source of the greatest long-term medical concern:
20 osteoporosis, cardiovascular effects such as hyperlipidemia, and estrogen-dependent cancer such as breast and uterine cancer.

 Osteoporosis, which generally includes a group of disorders which arise from diverse etiologies, is
25 characterized by the net loss of bone mass per unit volume.

 The consequence of this loss of bone mass and resulting bone fracture is the failure of the skeleton to provide adequate structural support for the body. One of the most common types of osteoporosis is that associated with
30 menopause. Most women lose from about 20% to about 60% of the bone mass in the trabecular compartment of the bone within three to six years after the cessation of menses. This rapid loss is generally associated with an increase of bone resorption and formation. However, the resorptive

cycle is more dominant and the result is a net loss of bone mass.

Osteoporosis is a common and serious disease among postmenopausal women. There are an estimated 25 million women in the United States who are afflicted with this disease. The results of osteoporosis disease's sequelae are personally harmful and often result in the need for extensive and long term medical support (hospitalization and nursing home care). This is especially true in elderly patients. Additionally, although osteoporosis is not generally thought of as a life threatening condition, a 20% to 30% mortality rate is related with hip fractures in elderly women. A large percentage of this mortality rate can be directly associated with postmenopausal osteoporosis.

The trabecular tissue is the most vulnerable bone tissue to the effects of postmenopausal osteoporosis. This tissue is often referred to as spongy or cancellous bone and is particularly concentrated near the ends of the bone (near the joints) and in the vertebrae of the spine. The trabecular tissue is characterized by small osteoid structures which inter-connect with each other, as well as the more solid and dense cortical tissue which makes up the outer surface and central shaft of the bone. This interconnected network of trabeculae gives lateral support to the outer cortical structure and is critical to the biomechanical strength of the overall structure. In postmenopausal osteoporosis, it is loss of the trabeculae which leads to the failure and fracture of bone. In light of the loss of the trabeculae in postmenopausal women, it is not surprising that the most common fractures are those associated with bones which are highly dependent on trabecular support, e.g., the vertebrae and the neck of the weight bearing bones, such as the femur and the fore-arm.

Indeed, hip fracture, collicles fractures, and vertebral crush fractures are hallmarks of postmenopausal osteoporosis.

At this time, the generally accepted method for treatment of postmenopausal osteoporosis is estrogen replacement therapy (ERT). Although ERT is generally successful, patient compliance with this therapy is low primarily because estrogen treatment frequently produces undesirable side effects.

Prior to menopause, most women have less incidence of cardiovascular disease than age-matched men. Following menopause, however, the rate of cardiovascular disease in women, such as hyperlipidemia, increases to match the rate seen in men. This rapid increase in the incidence of cardiovascular disease has been linked, in part, to the loss of estrogen and to the loss of estrogen's ability to regulate serum lipids. The nature of estrogen's ability to regulate serum lipids is not well understood, but evidence to date indicates that estrogen can upregulate the low density lipid (LDL) receptors in the liver to remove excess cholesterol. Additionally, estrogen appears to have some effect on the biosynthesis of cholesterol, as well as other beneficial effects on cardiovascular health.


It has been reported in the literature that postmenopausal women undergoing estrogen replacement therapy have a return of serum lipid levels to concentrations similar to those of the premenopausal state. Thus, estrogen would appear to be a reasonable treatment for this condition. However, the side-effects of ERT are not acceptable to many women, thus limiting the use of this therapy. An ideal therapy for this condition would be an agent which would regulate the serum lipid levels like estrogen, but would be devoid of the side-effects and risks associated with estrogen therapy.

The third major pathology associated with, but not limited to, postmenopausal syndrome is estrogen-dependent cancer, primarily breast and uterine cancer. Although such neoplasms are not solely limited to postmenopausal women, they are more prevalent in the older postmenopausal population. Current chemotherapy of these cancers has relied heavily on the use of estrogen agonist/antagonist compounds, such as tamoxifen. Although such mixed agonist/antagonists have beneficial effects in the treatment of these cancers, the estrogenic side-effects are tolerable in only acute life-threatening situations. These agents have stimulatory effects on certain cancer cell populations in the uterus due to their estrogenic (agonist) properties and therefore, are contraproductive in some cases. A better therapy for the treatment of these cancers would be an agent which is an antiestrogenic compound in cancerous tissue, having negligible or no estrogen agonist properties on other reproductive tissues.

In response to the clear need for new pharmaceutical agents which are capable of alleviating the symptoms of, *inter alia*, postmenopausal syndrome, the present invention provides new compounds, pharmaceutical compositions thereof, and methods of using such compounds for the treatment of postmenopausal syndrome and other estrogen-related pathological conditions such as those mentioned herein.

Summary of the Invention

The present invention relates to compounds of formula I:



5

I

wherein:

R and R¹ are independently hydrogen, halo, hydroxy, or
5 O-Pg;

R² is CHR³OR⁴, CO₂R⁵, CHOCH₂NR⁶R⁷, or a heterocycle;

X is C=O, CH-OH, CH₂, O, or S;

Pg is independently at each occurrence a hydroxy
protecting group;

10 R³ is hydrogen or CH₂OH;

R⁴ is hydrogen, C₁-C₆ alkyl, or COR⁸;

R⁵ is hydrogen, C₁-C₆ alkyl, or aryl;

R⁶ and R⁷ are independently at each occurrence hydrogen
or C₁-C₆ alkyl, or R⁶ and R⁷ together with the nitrogen to
15 which they are attached form a 3,5-dimethylpiperidino, 3-
methylnpiperidino, pyrrolidino, piperidino, or a
hexamethyleneimino ring;

R⁸ is hydrogen, C₁-C₆ alkyl, or aryl; or
a pharmaceutically acceptable salt or solvate thereof.

20 The present invention further relates to pharmaceutical
formulations containing compounds of formula I and the use
of such compounds for alleviating the symptoms of
postmenopausal syndrome, particularly osteoporosis,
cardiovascular-related pathological conditions, and
25 estrogen-dependent cancer.

Detailed Description of the Invention

As used herein, the term "C₁-C₄ alkyl" represents a
methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl,
30 cyclobutyl, s-butyl, or a t-butyl group. The term "C₁-C₆
alkyl" includes "C₁-C₄ alkyl" groups in addition to
straight, branched or cyclic alkyl groups having from five
to six carbon atoms which would include, but not be limited
to, pentyl, isopentyl, hexyl, 2-methylpentyl, cyclopentyl,

cyclohexyl, and like groups. The term "C₁-C₄ alkoxy" represents a methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, or a s-butoxy group. The term "halo" refers to fluoro, chloro, bromo, or iodo.

5 The term "aryl" represents phenyl, benzyl, substituted phenyl, and substituted benzyl groups.

 The term "heterocycle" refers to a 3 or 4 membered saturated, partially unsaturated, or aromatic optionally substituted ring, which contains one heteroatom chosen from
10 oxygen or sulfur, and also refers to a 5 or 6 membered saturated, partially unsaturated, or aromatic optionally substituted ring, which contains one or two heteroatoms chosen from oxygen or sulfur.

 The terms "substituted phenyl", "substituted benzyl",
15 and "optionally substituted heterocycle" represent a phenyl, benzyl, or heterocyclic group, respectively, substituted with one to three moieties chosen from the group consisting of halo, hydroxy, nitro, C₁-C₄ alkyl, C₁-C₄ alkoxy, trichloromethyl, and trifluoromethyl. Examples of a
20 substituted phenyl group include 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2-fluorophenyl, 4-hydroxyphenyl, 3-hydroxyphenyl, 2,4-dihydroxyphenyl, 3-nitrophenyl, 4-nitrophenyl, 2,4-dinitrophenyl, 4-
25 methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-propylphenyl, 4-n-butylphenyl, 4-t-butylphenyl, 3-fluoro-2-methylphenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,6-dimethylphenyl, 2-fluoro-5-methylphenyl, 2,4,6-trifluorophenyl, 2-trifluoromethylphenyl, 2-chloro-5-trifluoromethylphenyl, 3,5-bis-(trifluoromethyl)phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 2-methyl-4-nitrophenyl, 4-methoxy-2-nitrophenyl, and the like.

 Examples of a substituted benzyl group would include all

the compounds named when the word "benzyl" is substituted for the word "phenyl" in all the previously mentioned examples of a substituted phenyl group. The substitution of a heterocycle is similar to that of phenyl and benzyl group.

- 5 The term "hydroxy protecting group" denotes a group understood by one skilled in the organic chemical arts of the type described in Chapter 2 of "Protective Groups in Organic Synthesis, 2nd Edition, T. H. Greene, et al., John Wiley & Sons, New York, 1991, hereafter "Greene".
- 10 Representative hydroxy protecting groups include, for example, C₁-C₄ alkyl and substituted C₁-C₄ alkyl, including methyl, ethyl, or isopropyl ether, methoxymethyl ether, methylthiomethyl ether, *tert*-butylthiomethyl ether, (phenyldimethylsilyl)methoxymethyl ether, benzyloxymethyl
- 15 ether, *p*-methoxy-benzyloxymethyl ether, and *tert*-butoxymethyl ether; substituted ethyl ether groups such as ethoxyethyl ether, 1-(2-chloroethoxy)ethyl ether, 2,2,2-trichloroethoxymethyl ether, and 2-(trimethylsilyl)ethyl ether; phenyl and substituted phenyl ether groups such as
- 20 phenyl ether, *p*-chlorophenyl ether, *p*-methoxyphenyl ether, and 2,4-dinitrophenyl ether; benzyl ether groups such as benzyl ether; and alkylsilyl ether groups such as trimethyltriethyl- and triisopropylsilyl ethers, mixed alkylsilyl ether groups such as dimethylisopropylsilyl ether, and
- 25 diethylisopropylsilyl ether; ester protecting groups such as those of the general formula COC₁-C₆ alkyl or COAr, or a formate ester, benzylformate ester, mono- di- and trichloroacetate esters, phenoxyacetate ester, and *p*-chlorophenoxyacetate and the like; and carbonates of the
- 30 general formula COOC₁-C₆ alkyl, or COOAr, where Ar is phenyl or substituted phenyl. The species of hydroxy protecting group employed is not critical so long as the derivatized hydroxy group is stable to the condition of subsequent reaction(s) on other positions of the intermediate molecule

and can be selectively removed at the appropriate point without disrupting the remainder of the molecule including any other hydroxy protecting group(s). It is within the knowledge of one skilled in the art to select appropriate hydroxy protecting group(s) for a given set of reaction conditions given the guidance provided by Greene cited above.

The term "carbonyl activating group" refers to a substituent of a carbonyl that promotes nucleophilic addition reactions at that carbonyl. Suitable activating substituents are those which have a net electron withdrawing effect on the carbonyl. Such groups include, but are not limited to, esters and amides such as hydroxybenzotriazole, imidazole, a nitrophenol, pentachlorophenol, N-hydroxysuccinimide, dicyclohexylcarbodiimide, N-hydroxy-N-methoxyamine, and the like; acid anhydrides such as acetic, formic, sulfonic, methanesulfonic, ethanesulfonic, benzenesulfonic, or p-tolylsulfonic acid anhydride, and the like; and acid halides such as the acid chloride, bromide, or iodide.

Although the free-base form of formula I compounds can be used in the methods of the present invention, it is preferred to prepare and use a pharmaceutically acceptable salt form. Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid. Such salts are known as acid addition salts. Thus, the term "pharmaceutically acceptable salt" refers to acid addition salts of a compound of formula I which are substantially non-toxic at the doses administered and are commonly used in the pharmaceutical literature. See e.g. Berge, S.M., Bighley, L.D., and Monkhouse, D.C., *J. Pharm. Sci.*, 66, 1, 1977.

Examples of such pharmaceutically acceptable salts are the iodide, acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, g-hydroxybutyrate, b-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, hexyne-1,6-dioate, caproate, caprylate, chloride, cinnamate, citrate, decanoate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzenesulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, propanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like of a compound of formula I.

By "pharmaceutically acceptable" it is also meant that in a formulation containing the compound of formula I, the carrier, diluent, excipients, and salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.

The term "solvate" represents an aggregate that comprises one or more molecules of the solute, such as a formula I compound, with one or more molecules of solvent.

As used herein, the term "effective amount" means an amount of compound of the present invention which is capable of alleviating the symptoms of the various pathological conditions herein described.

The terms "treatment" or "treating" bear their usual meaning which includes prohibiting, inhibiting, ameliorating, halting, restraining, slowing or reversing the progression, or reducing the severity of a pathological symptom related to or resultant from post menopausal syndrome. As such, these methods include both medical therapeutic (acute) and/or prophylactic (prevention) administration as appropriate.

When any of the following substitutions occur:

- 10 X is CH-OH; and/or
- R² is a heterocycle; and/or
- R² is CHR³OR⁴ and R³ is CH₂OH; and/or
- R² is CHOCH₂NR⁶R⁷;

the compounds of the invention contain chiral centers.

15 All enantiomers, diastereomers, and mixtures thereof, are included within the scope of the present invention. While all diastereomers, both enantiomers, and mixtures thereof, are useful, single enantiomers or single diastereomers are preferred.

20 While all of the compounds of the present invention are useful, certain of the compounds are particularly interesting and are preferred. The following listing sets out several groups of preferred compounds. It will be understood that each of the listings may be combined with
25 other listings to create additional groups of preferred compounds.

- aa) R is halo;
- ab) R is fluoro;
- ac) R is chloro;
- 30 ad) R is bromo;
- ae) R is hydrogen;
- af) R is hydroxy;
- ag) R is O-Pg;
- ah) R¹ is halo;

- ai) R^1 is fluoro;
aj) R^1 is chloro;
ak) R^1 is bromo;
al) R^1 is hydrogen;
5 am) R^1 is hydroxy;
an) R^1 is O-Pg;
ao) R and R^1 are both hydroxy;
ap) R and R^1 are both O-Pg;
aq) Pg is methyl;
10 ar) Pg is benzyl;
as) Pg is isopropyl;
at) R^2 is CHR^3OR^4 ;
au) R^2 is CO_2R^5 ;
av) R^2 is $CHOHCH_2NR^6R^7$;
15 aw) X is C=O;
ax) X is O;
ay) R^3 is hydrogen;
az) R^3 is CH_2OH ;
ba) R^4 is hydrogen;
20 bb) R^4 is C_1-C_4 alkyl;
bc) R^4 is t-butyl;
bd) R^4 is ethyl;
be) R^4 is COR^8 ;
bf) R^5 is hydrogen;
25 bg) R^5 is C_1-C_4 alkyl;
bh) R^5 is methyl;
bi) R^5 is phenyl;
bj) R^5 is benzyl;
bk) R^6 hydrogen;
30 bl) R^7 is hydrogen;
bm) R^7 is C_1-C_6 alkyl;
bn) R^7 is n-hexyl;
bo) R^7 is isopropyl;
bp) R^7 is n-butyl;

bq) R^6 and R^7 together with the nitrogen to which they are attached form a 3,5-dimethylpiperidino ring;

br) R^6 and R^7 together with the nitrogen to which they are attached form a 3-methylpiperidino ring;

5 bs) R^6 and R^7 together with the nitrogen to which they are attached form a pyrrolidino ring;

bt) R^6 and R^7 together with the nitrogen to which they are attached form a piperidino ring;

bu) R^8 is C_1 - C_6 alkyl;

10 bv) R^8 is t-butyl;

bw) R^8 is methyl;

bx) R^8 is cyclohexyl;

by) R^8 is phenyl;

bz) the compound of formula I is a salt;


15

SYNTHESIS

Specific preparations of compounds of the present invention are described herein, in Examples 1 - 39. Modification to the methods described below may be necessary to accommodate reactive functionalities of particular substituents. Such modification would be both apparent to, and readily ascertained by, those skilled in the art. The following schemes generally illustrates the preparation of compounds of formula I.

25 The compounds of formula I where R and R^1 are not hydroxy, X is C=O, O, or S, R^2 is CHR^3OR^4 , CO_2R^5 , or a heterocycle, R^3 is hydrogen, and R^4 is C_1 - C_6 alkyl may be prepared from compounds of formula II as illustrated in Scheme 1 below where R' and $R^{1'}$ are independently at each
30 occurrence hydrogen, halo, or O-Pg, R^9 is $CH_2O(C_1$ - C_6 alkyl), CO_2R^5 , or a heterocycle, X' is C=O, O, or S, Y is hydroxy or a leaving group and R^3 , R^5 , and heterocycle are as described supra.

Scheme 1



- 5 Generally, a phenol intermediate of formula II is reacted with an alkylating agent of formula III, IV, or V under various protocols known in the art to give compounds of formula Ia. In one such procedure, intermediate II is reacted with an alcohol of the formula III, IV, or V under
- 10 Mitsunobo conditions (Y is hydroxy). The reaction may be accomplished by combining an appropriate alcohol of formula III, IV, or V, a dialkylazodicarboxylate, and a triaryl or trialkylphosphine in a polar organic solvent. Preferred reagents include diethyl azodicarboxylate and
- 15 triphenylphosphine and the preferred solvents are typically tetrahydrofuran or toluene. Preferred heterocyclic alcohols of formula V are those which contain an oxygen or sulfur atom at least two carbons removed from the alcohol group e.g. 2-hydroxymethyl-2,3,5,6-tetrahydropyrans or 2-
- 20 thiophenemethanol. The reaction is generally carried out by dissolving the reagents in a suitable solvent between 0°C and the reflux temperature of the reaction mixture and allowing the reaction to proceed until it is complete, generally in less than 24 hours.
- 25 Alternatively, when Y is a leaving group in compounds of formula III, IV, or V, displacement of the leaving group by a compound of formula II is accomplished by heating that compound of formula III, IV, or V and a compound of formula II in the presence of an appropriate base, such as potassium
- 30 bicarbonate or triethylamine, in a polar organic solvent


such as N,N-dimethylformamide. The reaction can be conducted at room temperature or, preferably, at 80°C to 120°C where the reaction is typically complete in less than 6 hours. The leaving group can be, but is not limited to, halides
5 such as chloride, bromide, or iodide or other functionalities capable of being displaced, such as sulfonates e.g. tosylate and mesylate. The preferred leaving group is bromide.

When R⁹ in compounds of formula Ia is CO₂R⁵ and R⁵ is
10 not hydrogen (esters) such compounds may be converted to their corresponding acids by standard saponifications procedures. This transformation is preferably accomplished through treatment of the ester with aqueous bases such as sodium hydroxide, lithium hydroxide, or potassium hydroxide,
15 followed by acidification with a proton source such as 5N hydrochloric acid.


Compounds of formula I where X is C=O, O, or S, R² is CHR³OR⁴, R³ is hydrogen, and R⁴ is hydrogen or COR⁸ may be prepared from compounds of formula Ia where R⁹ is CH₂O(C₁-C₆
20 alkyl) as shown in Scheme 2 below where Z is a carbonyl activating group and R, R¹, R⁹, and X' are as described *supra*.

Scheme 2

25



15




Compounds of formula Ib, prepared as described in Scheme 1, may be converted to compounds of formula Ic using standard hydroxy deprotection conditions known in the art. (See Greene at 14). Compounds of formula Ic may then be esterified using standard conditions well known in the art by treatment with a suitable base and a compound of formula VI. See e.g. Larock, "Comprehensive Organic Transformations", VCH Publishers, Inc., New York, N.Y., 1989, pgs. 978-979. Preferred reagents for this transformation include trialkylamine bases, such as triethylamine, and alkyl or aryl acid chlorides. The reaction is generally carried out in an organic solvent, such as tetrahydrofuran, at room temperature or below and is typically complete in less than 24 hours.

Compounds of formula I where X is C=O, O, or S and R² is $\text{CH(OH)CH}_2\text{NR}^6\text{R}^7$ may be prepared from compounds of formula Ia where R⁹ is a heterocycle where that heterocycle is an epoxide. This transformation is shown in Scheme 3 below where R, R¹, R⁶, R⁷, and X' are as described supra.

Scheme 3

16



5 Compounds of formula Ie, prepared as described in Scheme 1, may be reacted with a primary or secondary amine of formula VII e.g. 1-butylamine, pyrrolidine, or piperidine, to provide compounds of formula If. Preferred reaction conditions for this process include reaction of the


10 amine and epoxide in a polar organic solvent, such as methanol or ethanol, at the reflux temperature of the mixture for a period of about 30 minutes to about 4 hours.

 The compounds of formula I where X is C=O, O, or S, R² is CHR³OR⁴, R³ is CH₂OH, and R⁴ is hydrogen may be prepared

15 from compounds of formula Ia where R⁹ is a heterocycle where that heterocycle forms a 1,2-diol protecting group e.g. 2,2-dimethyldioxalan-4-yl. This transformation is illustrated in Scheme 4 below where n is 1 or 2 and R, R¹, and X' are as described *supra*.

20

Scheme 4



25

Compounds of formula Ig, prepared as described in Scheme 1 may be converted to compounds of formula Ic using standard 1,2-dihydroxy deprotection conditions known in the art. See Greene at 118.

The compounds of formula I where X is CH-OH or CH₂ may be prepared from compounds of formula Ia - Ih where X is C=O essentially as described in United States Patent 5,484,798, the teachings of which are hereby incorporated by reference.

When any of R, R', R¹, or R¹' are hydroxy protecting groups in compounds of formula Ia-Ih, they may be removed by well known methods in the art to give the compounds of formula I where R and R¹ are both hydroxy. Numerous reactions for the formation and removal of hydroxy protecting groups are described in a number of standard works including, for example, *Protective Groups in Organic Chemistry*, Plenum Press (London and New York, 1973); *The Peptides*, Vol. I, Schrooder and Lubke, Academic Press (London and New York, 1965), and Greene. Preferred protecting groups are C₁-C₄ alkyl groups and especially preferred are methyl groups.

The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I in its free base form with an equimolar or excess amount of acid. The reactants are generally combined in a polar organic solvent such as methanol or ethyl acetate. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration, or the solvent can be stripped off by conventional means.

The pharmaceutically-acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to use in pharmaceutical formulations.

The compounds of formula II may be prepared by a number of well known routes. For example, compounds of formula II where X is C=O and compounds of formula II where X is O, or S can be prepared from m-methoxythiophenol and an
5 appropriately substituted a-bromoacetophenone as taught respectively in United States Patents 4,133,814 and 5,510,357, the teaching of which are hereby incorporated by reference.

The optimal time for performing the reactions of
10 Schemes 1 - 4 can be determined by monitoring the progress of the reaction via conventional chromatographic techniques. Furthermore, it is preferred to conduct the reactions of the invention under an inert atmosphere, such as, for example, argon, or, particularly, nitrogen. Choice of solvent is
15 generally not critical so long as the solvent employed is inert to the ongoing reaction and sufficiently solubilizes the reactants to effect the desired reaction. Intermediate and final products may be purified, if desired by common techniques such as recrystallization or chromatography over
20 solid supports such as silica gel or alumina.

Compounds of formula III, IV, V, VI, and VII are either commercially available or may be prepared by methods well known in the art.

The synthetic steps of the routes described herein may
25 be combined in other ways to prepare the formula I compounds. The discussion of the synthesis is not intended to be limiting to the scope of the present invention, and should not be so construed. Application of the above chemistry enables the synthesis of the compounds of formula
30 I, which would include, but not be limited to:


1) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(butoxyethoxy)phenyl]methanol,

- 2) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(ethoxyethoxy)phenyl]sulfide,
- 3) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(carboethoxyethoxy)phenyl]ether,
- 5 4) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-((tetrahydrofuran-2-yl)methoxy)phenyl]methane,
- 5) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl]methanol,
- 6) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2,3-dihydroxypropoxy)phenyl]sulfide,
- 10 7) (R)-[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2,3-dihydroxypropoxy)phenyl]ether,
- 8) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(cyclohexanoyloxyethoxy)phenyl]methane
- 15 9) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-((benzoyloxy)ethoxy)phenyl]methanol,
- 10) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-((acetoxy)ethoxy)phenyl]sulfide,
- 20 11) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-((trimethylacetoxy)ethoxy)phenyl]ether,
- 12) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-butylaminopropoxy)phenyl]methane,
- 13) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-pyrrolidinylpropoxy)phenyl]methanol,
- 25 14) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-piperidinylpropoxy)phenyl]sulfide,
- 15) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-isopropylaminopropoxy)phenyl]ether,
- 30 16) [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-((3a, 5b)-3,5-dimethylpiperidinyl)propoxy)phenyl]methane,

To a mixture of [6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl](4-hydroxyphenyl)methanone (1.0 g, 2.6 mmol), ethylene glycol mono t-butyl ether (0.6 g, 5 mmol), and triphenylphosphine (1.02 g, 3.9 mmol) stirring in tetrahydrofuran (40 mL) at 0°C was added diethyl azodicarboxylate (0.61 mL, 3.9 mmol) dropwise over a 10 minute period. After 2 hours at room temperature, the reaction was concentrated and the resulting residue purified by flash chromatography (silica gel, 3:1 hexanes/ethyl acetate) to give 1.37 g of the title compound as a thick syrup.
Yield: 94%.

Example 2

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][(4-Hydroxyethoxy)phenyl]methanone




An aqueous solution of sodium hydroxide was added to 1.37 g of [6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][(4-t-butoxyethoxy)phenyl]methanone stirring in dioxane at room temperature. The mixture was then heated to reflux. After a sufficient time, the mixture was cooled to room temperature and the solution made acidic by addition of 1N hydrochloric acid then extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (sodium sulfate), filtered, and concentrated. This material was purified by flash chromatography (silica gel, ethyl

acetate) resulting in 3.0 g of the title compound as a thick syrup.

Example 3

5 [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][(4-Hydroxyethoxy)phenyl]methanone



10

To [6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][(4-hydroxyethoxy)phenyl]methanone (3.0 g, 6.9 mmol) stirring vigorously in methylene chloride (200 mL) at room temperature was added ethanethiol (3 mL, 40 mmol) followed by aluminum chloride (5.3 g, 40 mmol). After 1 hour, sodium bicarbonate (saturated aqueous solution) and methanol were added. The mixture was then extracted throughout with ethyl acetate. The combined organic extracts were washed with brine, dried (sodium sulfate), filtered, and concentrated.

15

20 The resulting material was purified by flash chromatography (silica gel, ethyl acetate) to give 2.4 g of the title compound as a yellow solid.

Yield: 85%. ¹H NMR (C₃D₆O) δ 8.6-8.7 (m, 2H), 7.72 (d, J = 9.0 Hz, 2H), 7.27 (d, J = 8.9 Hz, 2H), 6.84-6.96 (m, 3H), 6.73 (d, J = 9.0 Hz, 2H), 4.8 (t, J = 3.1 Hz, 2H).


25

Example 4

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Ethoxyethoxy)phenyl]methanone

30

23




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl](4-hydroxyphenyl)methanone (0.39 g, 1.00 mmol) and ethylene glycol mono ethyl ether (2 mmol) were converted to 350 mg of the title compound by the procedure of Example 1 using 520 mg (2.0 mmol) of triphenylphosphine and 2.0 mmol of diethyl azodicarboxylate the only difference being that the total reaction time was 18 hours.

10

Example 5

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(ethoxyethoxy)phenyl]methanone



15

[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(ethoxyethoxy)phenyl]methanone (0.35 g, 0.76 mmol) was converted to 2.4 g of the title compound by the procedure of Example 3 using 0.28 mL (3.79 mmol) of ethanethiol and 0.61 g (4.6 mmol) of aluminum chloride.


Yield: 43%. ¹H NMR (MeOD): d 7.68-7.71 (d, 2H, J = 9.2 Hz), 7.39-7.42 (d, J = 8.8 Hz, 1H), 7.25-7.26 (d, 1H, J = 2.2 Hz), 7.17-7.19 (d, 2H, J = 8.5 Hz), 6.83-6.88 (m, 3H), 6.61-6.64 (d, 2H, J = 9.0 Hz), 4.09-4.12 (m, 2H), 3.72-3.75

25

(m, 2H), 3.52-3.58 (q, 2H, J = 7.0 Hz), 1.15-1.20 (t, 3H, J = 7.0 Hz).

Example 6

5 [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-Carbomethoxymethoxyphenyl]methanone




10 To [6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-hydroxyphenyl]methanone (5.0 g, 12.8 mmol) stirring in dimethylformamide at room temperature was added potassium carbonate (5.3 g, 38.4 mmol) followed by methyl bromoacetate (8 mL, 84.5 mmol). The solution was stirred at 80°C for 1
15 hour then cooled to room temperature and poured into brine/ethyl acetate (300 mL, 1:1). The mixture was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts washed thoroughly with brine, dried (magnesium sulfate), and filtered. Concentration gave a
20 yellow syrup which was further dried in vacuo to give 5.33 g of the methyl ester as a white crystalline solid which was used without further purification.
Yield: 90%.

25

Example 7

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-Carbomethoxymethoxyphenyl]methanone

25




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-carbomethoxymethoxyphenyl]methanone (250 mg, 0.54 mmol) was converted to the title compound by the procedure of Example 3 using 0.24 mL (3.25 mmol) of ethanethiol and 505 mg (3.79 mmol) of aluminum chloride except the total reaction time was 0.5 hours and the workup of the reaction went as follows: the mixture was poured into a mixture of
 10 brine/ethyl acetate and extracted with ethyl acetate. The residual solid remaining in the reaction vessel was dissolved in a minimal amount of methanol and added to the ethyl acetate extracts. The combined organic extracts were washed thoroughly with brine, dried (magnesium sulfate),
 15 filtered, and concentrated. Purification by radial chromatography (2 mm, silica gel, 40% methanol in ethyl acetate) gave 140 mg methyl ether cleaved product as a yellow solid.

20

Example 8

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-Carboxymethoxyphenyl]methanone



25


To [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-carbomethoxymethoxyphenyl]methanone (132 mg, 0.30 mmol) stirring in methanol (5 mL) was added sodium hydroxide (0.43 mL of a 5 N aqueous solution, 2.13 mmol). The red mixture was heated to reflux for 0.5 hour, cooled to room temperature, and made acidic with hydrochloric acid (0.70 mL of a 5N aqueous solution). The mixture was then poured into brine and extracted with ethyl acetate. The combined organic extracts were washed thoroughly with brine, dried (magnesium sulfate), and filtered. Concentration afforded the title compound as a yellow solid.

¹H NMR(C₃D₆O): d 8.70 (br s, 2H) 7.76 (d, 2H, J = 8.8 Hz), 7.39 (m, 2H), 7.28 (d, 2H, J = 9.0 Hz), 6.84-6.94 (d, 2H, J = 9.0 Hz), 4.74 (s, 2H).

15

Example 9

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Tetrahydropyran-2-yl)methoxyphenyl]methanone




20

[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-hydroxyphenyl]methanone (0.39 g, 1.00 mmol) and 2-hydroxymethyltetrahydropyran (174 mg, 1.5 mmol) were converted to the title compound by the procedure of Example 1 using 390 mg (1.5 mmol) of triphenylphosphine and 0.24 mL (1.5 mmol) of diethyl azodicarboxylate the only difference being that the total reaction time was 3 hours giving a thick syrup.

Example 10

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(Tetrahydropyran-2-yl)methoxyphenyl]methanone

5



[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(tetrahydropyran-2-yl)methoxyphenyl]methanone (0.32 g, 0.66 mmol) was converted to the title compound by the procedure of Example 3 using 0.24 mL (3.31 mmol) of ethanethiol and 530 mg (3.97 mmol) of aluminum chloride.


Yield: 62%. ^1H NMR(d_6 -DMSO): δ 9.76 (br s, 2H), 7.65 (d, 2H, $J = 9.0$ Hz), 7.35 (d, $J = 2.0$ Hz, 1H), 7.27 (d, $J = 9.0$ Hz, 1H), 7.19 (d, 2H, $J = 9.0$ Hz), 6.85-6.92 (complex, 3H), 6.85 (d, $J = 9.0$ Hz, 2H) 3.85-3.95 (complex, 3H), 3.60 (m, 1H), 1.20-1.82 (complex, 6H).

15

Example 11

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-([Tetrahydrofuran-2-yl)methoxy]phenyl]methanone

20




25

[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl](4-hydroxyphenyl)methanone (390 mg, 1 mmol) and 2-hydroxymethyl

tetrahydrofuran (153 mg, 1.50 mmol) were converted to 297 mg of the title compound by the procedure of Example 9 using 393 mg (31.5 mmol) of triphenylphosphine and 0.24 mL (1.5 mmol) of diethyl azodicarboxylate the only differences being that the chromatography eluent was 3:7 ethyl acetate:hexanes.
Yield: 83%.

Example 12


[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-
([Tetrahydrofuran-2-yl]methoxy)phenyl]methanone



[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-
([tetrahydrofuran-2-yl])methoxy)phenyl]methanone (297 mg) was converted to 189 mg of the title compound by the procedure of Example 3 using 0.24 mL (3.31 mmol) of ethanethiol and 530 mg (3.97 mmol) of aluminum chloride except that 1:1 ethyl acetate:hexanes was used as chromatography eluent.
¹H NMR(*d*₆-DMSO): δ 9.74 (br s, 2H), 7.65 (d, 2H, J = 9.1 Hz), 7.35 (d, J = 2.5 Hz, 1H), 7.25 (d, 1H, J = 9.0 Hz), 7.15 (d, 2H, J = 9.3 Hz), 6.93 (d, 1H, J = 8.9 Hz), 6.83 (dd, 1H, J = 9.0 Hz, 2.3 Hz), 6.70 (d, 2H, J = 8.9 Hz), 4.13 (m, 1H), 3.96 (m, 2H), 3.38 (complex, 2H), 1.75 - 2.0 (complex, 3H), 1.60 (m, 1H).

Example 13

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-
([2,2-Dimethyl-1,3-dioxolan-3-yl]methoxy)phenyl]methanone




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl] (4-hydroxyphenyl)methanone and 2,2-dimethyl-1,3-dioxolane-4-methanol were converted to the title compound by the procedure of Example 9 using triphenylphosphine and diethyl azodicarboxylate.

10

Example 14

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-(2,3-Dihydroxypropoxy)phenyl]methanone



15


[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl] [4-([2,2-dimethyl-1,3-dioxolan-3-yl]methoxy)phenyl]methanone was converted to the title compound by the procedure of Example 3 using ethanethiol and aluminum chloride.

20

Example 15

(R) - [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [4-([2,2-Dimethyl-1,3-dioxolan-3-yl]methoxy)phenyl]methanone

25




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl](4-hydroxyphenyl)methanone (0.39 g, 1.00 mmol) and (R)-2,2-dimethyl-1,3-dioxolane-4-methanol (0.18 ml, 1.5 mmol) were converted to the title compound by the procedure of Example 13 using 390 mg (1.5 mmol) of triphenylphosphine and 0.24 mL (1.5 mmol) of diethyl azodicarboxylate.

10

Example 16

(R)-[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2,3-Dihydroxypropoxy)phenyl]methanone



15


(R)-[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-([2,2-dimethyl-1,3-dioxolan-3-yl]methoxy)phenyl]methanone (0.39 g, 0.77 mmol) was converted to the title compound by the procedure of Example 14 using 0.28 mL (3.84 mmol) of ethanethiol and 610 mg (4.61 mmol) of aluminum chloride.

Yield: 82%. ¹H NMR(*d*₆-DMSO): d 9.75 (br s, 2H), 7.68 (d, 2H, J = 9.0 Hz), 7.15-7.35 (complex, 4H), 6.82-6.92

(complex, 3H), 6.70 (d, $J = 9.1$ Hz, 2H) 4.98 (d, $J = 3.1$ Hz, 1H), 3.78 (m, 1H), 3.40 (m, 2H).

Example 17

5 [6-Methoxy-2-(4-Methoxyphenyl)benzo[*b*]thiophen-3-yl][4-(Cyclohexanoyloxyethoxy)phenyl]methanone




10 To [6-methoxy-2-(4-methoxyphenyl)benzo[*b*]thiophen-3-yl][4-(4-hydroxyethoxy)phenyl]methanone (0.77 g, 1.8 mmol) stirring in tetrahydrofuran (200 mL) was added triethylamine (0.36 g, 3.6 mmol) followed by cyclohexane carbonyl chloride (0.26 g, 1.8 mmol). After 18 hours, the mixture was
15 filtered and concentrated. The resulting material was taken up in ethyl acetate, washed with 1N hydrochloric acid, dried (sodium sulfate), filtered, and concentrated to give 1.25 g of the title compound as a thick oil.

20

Example 18

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[*b*]thiophen-3-yl][4-(Cyclohexanoyloxyethoxy)phenyl]methanone


32



[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(cyclohexanoyloxyethoxy)phenyl]methanone (1.25 g, 2.3 mmol) was converted to the title compound by the procedure of Example 3 using 400 mg (7.0 mmol) of ethanethiol and 920 mg (7.00 mmol) of aluminum chloride (0.92 g, 7.00 mmol). Yield: 48%. ^1H NMR(d_6 -DMSO): δ 9.75 (app d, 2H), 7.63 (d, 2H, $J = 8.5$ Hz), 7.23 (s, 1H), 7.20-7.23 (m, 1H), 7.13-7.16 (m, 2H), 6.89-6.92 (m, 2H), 6.81-6.83 (m, 1H), 6.64-6.66 (m, 2H), 4.27-4.29 (s, 2H), 4.18-4.20 (s, 2H), 1.62-1.80 (m, 2H), 1.40-1.62 (m, 3H), 1.01-1.39 (m, 6H).

Example 19

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Benzoyloxyethoxy)phenyl]methanone




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(4-hydroxyethoxy)phenyl]methanone (0.76 g, 1.8 mmol) and benzoyl chloride (0.25 g, 1.8 mmol) were converted to 1.14 g

of the title compound by the procedure of Example 17 using 360 mg (3.6 mmol) of triethylamine.

Example 20

- 5 [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-(Benzoyloxyethoxy)phenyl]methanone




- 10 [6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl] [4-(benzoyloxyethoxy)phenyl]methanone (1.14 g, 2.10 mmol) was converted to the title compound by the procedure of Example 3 using 400 mg (7.0 mmol) of ethanethiol and 920 mg (7.0 mmol) of aluminum chloride.
- 15 Yield: 20%. ¹H NMR(*d*₆-DMSO): δ 9.71-9.76 (d, 2H), 7.90 - 7.92 (m, 2H), 7.64-7.66 (m, 2H), 7.45-7.47 (m, 2H), 7.31 (s, 1H), 7.14-7.23 (m, 4H), 6.95-6.98 (d, 2H), 6.64-6.67 (d, 2H), 4.56-4.57 (d, 2H), 4.34-4.35 (m, 2H).

20

Example 21

- [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [4-(Acetoxymethoxy)phenyl]methanone

34




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][(4-hydroxyethoxy)phenyl]methanone (1.07 g, 2.5 mmol) and
 5 acetyl chloride (200 mg, 2.5 mmol) were converted to 1.7 g
 of the title product by the procedure of Example 17 using
 500 mg (5.00 mmol) of triethylamine except that the total
 reaction time was 72 hours.

10

Example 22

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-
 (Acetoxymethoxy)phenyl]methanone



15


[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-
 (Acetoxymethoxy)phenyl]methanone (1.7 g, 2.5 mmol) was
 converted to the title compound by the procedure of Example
 20 3 using 500 mg (7.5 mmol) of ethanethiol and 1.0 g (7.5
 mmol) of aluminum chloride except that the total reaction
 time was 4 hours.

Yield: 29%. ^1H NMR(d_6 -DMSO): d 9.71-9.75 (app d, 2H), 7.63 (d, 2H), 7.32 (s, 1H), 7.23 (d, 1H), 7.15 (d, 2H), 6.90 (d, 2H), 6.83 (d, 1H), 6.64 (d, 2H), 4.28-4.29 (m, 2H), 4.18-4.19 (m, 2H), 1.98 (s, 3H).

5

Example 23

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Trimethylacetoxymethoxy)phenyl]methanone



10


[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(4-hydroxyethoxy)phenyl]methanone (1.22 g, 2.8 mmol) and trimethyl acetyl chloride (0.34 g, 2.8 mmol) were converted to the title compound by the procedure of Example 21 using 600 mg (5.6 mmol) of triethylamine (0.60 g, 5.6 mmol).

15

Example 24

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(Trimethylacetoxymethoxy)phenyl]methanone

20




[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Trimethylacetoxymethoxy)phenyl]methanone (760 mg, 1.5 mmol) was converted to the title compound by the procedure of Example 3 using 300 mg (4.5 mmol) of ethanethiol and 600 mg (4.5 mmol) of aluminum chloride.

Yield: 69%. ^1H NMR(d_6 -DMSO): δ 9.69 (d, 2H), 7.63 (d, 2H), 7.31 (d, 1H), 7.22 (d, 1H), 7.17 (d, 2H), 6.91 (d, 2H), 6.80 (d, 1H), 6.65 (d, 2H), 4.22-4.28 (m, 2H), 4.20 (m, 2H), 1.04-1.06 (m, 9H).

Example 25

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][O-Epihydrin)-4-Hydroxyphenyl]methanone




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl](4-hydroxyphenyl)methanone (10 g, 25.6 mmol) and epibromohydrin (3.3 mL, 38.0 mmol) were converted to 2.0 g of the title compound by the procedure of Example 6 except that the reaction was performed for 16 hours at room temperature and the work up was as follows: the reaction mixture was filtered and the filtrate was concentrated. The residue was taken up in ethyl acetate and washed with saturated sodium bicarbonate. The organic portion was dried over sodium sulfate and concentrated to give a yellow solid which was recrystallized from ethyl acetate.

37

Example 26

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Butylaminopropoxy)phenyl]methanone



5

To a suspension of [6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][O-epihydrin)-4-hydroxyphenyl]methanone (2.0 g, 4.5 mmol) in ethanol (50 mL) was added butylamine (0.98 g, 13.0 mmol) and the reaction mixture was heated to reflux. After 3 hours, the mixture was cooled to room temperature and concentrated. Purification by radial chromatography (silica gel, 4mm, 50% ethyl acetate in hexanes) provided 1.56 g of the title compound as a yellow oil.


15

Yield: 67%. ^1H NMR(CDCl_3): d 7.76 (d, 2H, $J = 8.4\text{Hz}$), 7.52 (d, 1H, $J = 9.0\text{Hz}$), 7.33 (m, 3H), 6.95 (m, 1H), 6.75 (m, 4H), 3.94 (m, 3H), 3.87 (s, 3H), 3.74 (s, 3H), 2.70 (br m, 6H), 1.39 (br m, 4H), 0.90 (t, 3H, $J = 7.1\text{Hz}$).

20

Example 27

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Pyrrolidinylpropoxy)phenyl]methanone




25

[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][O-epihydrin)-4-hydroxyphenyl]methanone (0.5 g, 1.1 mmol) and pyrrolidine (0.5 mL, 5.0 mmol) were converted to the title compound by the procedure of Example 26 except that 6:4 ethyl acetate/methanol was used as chromatography eluent.

Example 28

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Pyrrolidinylpropoxy)phenyl]methanone

10




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-pyrrolidinylpropoxy)phenyl]methanone (250 mg, 0.50 mmol) was converted to 164 mg of the title compound by the procedure of Example 32 using 0.18 mL (2.48 mmol) of ethanethiol (0.18 mL, 2.48 mmol) and 398 mg (2.98 mmol) of aluminum chloride except that 6:4 ethyl acetate/methanol gradient was used as the chromatography eluent.

¹H NMR(*d*₆-DMSO): δ 7.62 (d, 2H, *J* = 9.0 Hz), 7.10-7.50 (complex, 4H), 6.80-6.90 (complex, 3H), 6.67 (d, 2H, *J* = 9.0 Hz), 4.12 (m, 1H), 4.00 (m, 1H), 3.81-3.91 (complex, 2H), 2.35-2.60 (complex, 4H), 1.58-1.61 (complex, 4H).

Example 29

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Piperidinylpropoxy)phenyl]methanone




5

To a solution of [6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][O-epihydrin)-4-hydroxyphenyl]methanone (0.5 g, 1.1 mmol) stirring in
10 ethanol at room temperature was added potassium carbonate (300 mg, 2.0 mmol) followed by piperidine hydrochloride (200 mg, 1.5 mmol). The mixture was heated to reflux and maintained at that temperature for 1 hour then cooled to ambient temperature. The solution was concentrated and the
15 resulting mixture dissolved in ethyl acetate and extracted with water. The organic extract was dried over magnesium sulfate to give a brown oil which was purified by radial chromatography (silica gel, 2mm, 8:2 ethyl acetate/methanol (v/v) to give 210 mg of the title compound as an off-white
20 foam.

Example 30

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Piperidinyl)propoxy]phenyl]methanone



5


[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-piperidinylpropoxy)phenyl]methanone (210 mg, 0.41 mmol) was converted to 151 mg of the title compound by the procedure of Example 32 using 0.15 mL (2.03 mmol) of ethanethiol and 326 mg (2.44 mmol) of aluminum chloride. ¹H NMR(*d*₆-DMSO): d 7.64 (d, 2H, *J* = 8.8 Hz), 7.34 (d, 1H, *J* = 2.5 Hz 4H), 7.16 (d, 1H, *J* = 9.0 Hz), 6.93 (d, 2H, *J* = 8.7 Hz), 6.84 (dd, *J* = 9.0 Hz, 2.4 Hz), 6.63 (d, 2H, *J* = 8.7 Hz), 3.90-4.10 (complex, 2H), 2.23-2.60 (complex, 6H), 1.45-1.56 (complex, 4H), 1.35-1.45 (complex, 2H).

15

Example 31

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Isopropylamino)propoxy]phenyl]methanone

20




[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-epihydrin)-4-hydroxyphenyl]methanone (0.50 g, 1.1 mmol) and

25

isopropylamine (0.48g, 5.6 mmol) were converted to the title compound by the procedure of Example 26.

Example 32


- 5 [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Isopropylamino)propoxy)phenyl]methanone



- 10 [6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-isopropylamino)propoxy)phenyl]methanone (0.42 g, 0.8 mmol) was converted to 200 mg of the title compound by the procedure of Example 7 using 0.30 mL (4.2 mmol) of ethanethiol and 850 mg (6.4 mmol) of aluminum chloride
- 15 except that the workup was performed as follows: the reaction was quenched by slow addition of saturated sodium bicarbonate. To the resulting solution was added sufficient methanol to dissolve all remaining yellow residue. This mixture was extracted with ethyl acetate, the combined
- 20 organic extracts were dried over sodium sulfate, filtered, and concentrated. Purification by radial chromatography (silica gel, 2mm, 6:2:1.5:0.5 ethyl acetate: hexanes: methanol: triethylamine) provided the desired compound as a yellow solid.
- 25 Yield: 52%. ¹H NMR (CDCl₃) δ 7.62 (d, 2H, J = 8.7 Hz), 7.30 (s, 1H), 7.26 (m, 1H), 7.15 (m, 4H), 6.84 (m, 4H), 6.64 (dd, 2H, J = 6.9 Hz, 1.8 Hz), 3.88 (m, 3H), 2.64 (m, 3H), 0.95 (d, 6H, J = 6.3 Hz).

Example 33

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(3-
[2-Hydroxy-(3a, 5b)-3,5-
Dimethylpiperidinyl]propoxy)phenyl]methanone, and [6-
5 Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-
Hydroxy-3-[(3a, 5a)-3,5-
Dimethylpiperidinyl]propoxy)phenyl]methanone




10

[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][O-
epihydrin)-4-hydroxyphenyl]methanone (2.0 g, 4.5 mmol) and
3,5-dimethylpiperidine (2.97, 22.0 mmol) were converted to
670 mg of the trans title product and 1.67 g of the cis
15 title product by the procedure of Example 26.
(93% total yield).

Example 34

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[(3a, 5b)-3,5-Dimethylpiperidinyl]propoxy)phenyl]methanone, and [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[(3a, 5a)-3,5-Dimethylpiperidinyl]propoxy)phenyl]methanone



10

A mixture of [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-[(3a, 5b)-3,5-dimethylpiperidinyl]propoxy)phenyl]methanone (670 mg) and [6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-[(3a, 5a)-3,5-dimethylpiperidinyl]propoxy)phenyl]methanone (1.67 g) were converted to the title compounds by the procedure of Example 3 to give 500 mg of the trans product and 1.22 g of the cis product.


Yield (trans): 78%. Yield (cis): 78%. ^1H NMR (CDCl_3) trans d 7.61 (d, 2H, $J = 8.7$ Hz), 7.29 (d, 1H, $J = 2.1$ Hz), 7.16 (dd, 3H, $J = 21$ Hz, 8.9 Hz), 6.83 (m, 3H), 6.63 (d, 2H, $J = 8.4$ Hz), 4.79 (br m, 1H), 4.00 (m, 1H), 3.84 (t, 1H, $J = 6.2$ Hz), 3.28 (s, 2H), 3.12 (s, 1H), 2.34 (m, 4H), 1.99 (m, 1H), 1.73 (m, 1H), 1.15 (t, 1H, $J = 5.4$ Hz), 0.88 (m, 6H). ^1H NMR (CDCl_3) cis d 7.61 (d, 2H, $J = 8.7$ Hz), 7.29 (d, 1H, $J = 2.1$ Hz), 7.16 (dd, 3H, $J = 21$ Hz, 8.9 Hz), 6.83 (m, 3H), 6.63 (d, 2H, $J = 8.4$ Hz), 4.78 (br m, 1H), 3.84 (m, 4H),

25

3.29 (s, 2H), 3.12 (d, 2H, $J = 2.6$ Hz), 2.72 (m, 2H), 2.45 (m, 2H), 2.31 (m, 2H), 1.462 (m, 4H), 0.94 (m, 6H).

Example 35


5 [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[3-Methylpiperidinyl]propoxy)phenyl]methanone



10 [6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][O-epihydrin)-4-hydroxyphenyl]methanone (500 mg, 1.1 mmol) and 3-methylpiperidine (0.65 mL, 5.6 mmol) were converted to 340 mg of the title compound by the procedure of Example 26.

Example 36

15 [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[3-Methylpiperidinyl]propoxy)phenyl]methanone



20

[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-hydroxy-3-[3-methylpiperidinyl]propoxy)phenyl]methanone (540 mg, 1.0 mmol) was converted to 340 mg of the title compound by the procedure of Example 32 using 360 mg (4.9 mmol) of ethanethiol and aluminum chloride.

25


45

Yield: 66%. ^1H NMR (CDCl_3) δ 7.13 (d, 2H, $J = 8.4\text{Hz}$), 6.84 (m, 3H), 6.63 (dd, 2H, $J = 8.4\text{Hz}$), 3.91 (m, 3H), 2.69 (m, 2H), 2.31 (m, 2H), 1.901 (m, 2H), 1.52 (m, 5H), 0.75 (d, 6H, $J = 5.4\text{ Hz}$).

5

Example 37

[6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Methoxy-3-Hexylaminopropoxy)phenyl]methanone



10


[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][O-epihydrin)-4-hydroxyphenyl]methanone (500 mg, 1.1 mmol) and n-hexylamine (0.74 mL, 5.6 mmol) were converted to 540 mg of the title compound by the procedure of Example 26.
Yield: 90%.

15

Example 38

[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Pentylaminopropoxy)phenyl]methanone

20



[6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-methoxy-3-hexylaminopropoxy)phenyl]methanone (340 mg, 0.62 mmol) was converted to 200 mg of the title compound by

25

the procedure of Example 32 using 0.23 mL (3.1 mmol) of ethanethiol 660 mg (5.0 mmol) of aluminum chloride.

Yield: 62%. ¹H NMR(d₆-DMSO): d 7.61 (d, 2H, J = 8.7Hz), 7.30 (d, 1H, J = 2.1Hz), 7.20 (d, 1H, J = 8.7 Hz), 7.13 (d, 2H, J = 8.7 Hz), 6.84 (m, 3H), 6.63 (d, 1H, J = 8.7 Hz), 3.89 (m, 3H), 2.50 (m, 2H), 1.19 (m, 8H), 0.80 (t, 3H, J = 6.5 Hz).

Experimental Assays

Representative compounds of the present invention have been biologically tested to demonstrate their efficacy for treating the effects of post menopausal syndrome. In the examples illustrating the methods, a post menopausal model was used in which effects of different treatments upon circulating lipids were determined.

General Preparation Procedure

Seventy-five day old female Sprague Dawley rats (weight range of 200 g - 225 g) were obtained from Charles River Laboratories (Portage, MI). The animals were either bilaterally ovariectomized (OVX) or exposed to a Sham surgical procedure at Charles River Laboratories, and then shipped after one week. Upon arrival, these rats were housed in metal hanging cages in groups of three or four animals per cage, and had *ad libitum* access to food (calcium content approximately 0.5%) and water for one week. Room temperature was maintained at 22.2°C ± 1.7°C with a minimum relative humidity of 40%. The photoperiod in the room was twelve hours light and twelve hours dark.

Dosing Regimen Tissue Collection.

After a one-week acclimation period (two weeks post-OVX), daily dosing with test compound was initiated. The test compounds or 17a-ethynylestradiol (Sigma Chemical Co.,

St. Louis, MO) were given orally, unless otherwise stated, as a suspension in 1% carboxymethylcellulose or dissolved in 20% cyclodextrin. Animals were dosed daily for four days. Following the dosing regimen, animals were weighed and
5 anesthetized with a ketamine:xylazine (2:1, v:v) mixture and a blood sample was collected by cardiac puncture. The animals were then sacrificed by asphyxiation with CO₂, the uterus was removed through a midline incision, and a wet uterine weight was determined.

10

Serum Cholesterol Analysis

Blood samples were allowed to clot at room temperature for two hours, and serum was obtained following centrifugation for ten minutes at 3000 rpm. Serum
15 cholesterol was determined using a high-performance cholesterol assay (Boehringer Mannheim Diagnostics, Indianapolis, IN). Briefly, the cholesterol was oxidized to produce cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide was then reacted with phenol and 4-
20 aminophenazone in the presence of peroxidase to produce a p-quinoneimine dye, which was read spectrophotometrically at 500 nm. Cholesterol concentration was then calculated against a standard curve.

25 Uterine Eosinophil Peroxidase (EPO) Assay

Uteri were kept at 4°C until time of enzymatic analysis. The uteri were then homogenized in 50 volumes of 50 mM Tris buffer (pH = 8.0) containing 0.005% Triton X-100. Upon addition of 0.01% hydrogen peroxide and 10 mM
30 o-phenylenediamine (final concentrations) in Tris buffer, the increase in absorbance was monitored for one minute at 450 nm. The presence of eosinophils in the uterus was taken as an indication of estrogenic activity of a compound. The

maximal velocity of a fifteen second interval was determined over the initial, linear portion of the reaction curve.

Representative compounds of the present invention were
5 tested in a four day ovariectomized rat model to study their
estrogenicity. In particular, the effect on the uterus and
the cholesterol lowering characteristics were studied.
Comparative data were obtained between untreated
ovariectomized rats, ovariectomized rats treated with 17a-
10 ethynylestradiol (EE₂), and ovariectomized rats treated with
certain compounds of the present invention. Although EE₂
caused a decrease in serum cholesterol when orally
administered at 0.1 mg/kg/day, it also exerted a stimulatory
action on the uterus so that EE₂ uterine weight was
15 substantially greater than the uterine weight of untreated
ovariectomized test animals. This uterine response to
estrogen is well recognized in the art. Representative
compounds of the present invention reduced serum cholesterol
compared to the ovariectomized control animals. Also,
20 relative to EE₂, representative compounds of the present
invention have a diminished effect on uterine weight.

Compared to estrogenic compounds known in the art, the
benefit of serum cholesterol reduction without as adverse of
an affect on uterine weight is rare and desirable.

25 As is expressed in the *in vivo* data, estrogenicity also
was assessed by evaluating the adverse response of
eosinophil infiltration into the uterus. Relative to EE₂,
which caused a substantial, expected increase in eosinophil
infiltration, the representative compounds of the present
30 invention did not increase the eosinophil infiltration, and
in most cases had a significantly diminished effect.

In addition to the demonstrated benefits of these
representative compounds of the present invention,

especially when compared to estradiol, the compounds tested were not estrogen mimetic.

MCF-7 Proliferation Assay

5 The affinity of a representative sample of the compounds of the present invention for the estrogen receptors was tested in a MCF-7 receptor proliferation assay. MCF-7 breast adenocarcinoma cells (ATCC HTB 22) were maintained in MEM (minimal essential medium, phenol red-free, Sigma Chemical Co., St. Louis, MO) supplemented with
10 10% fetal bovine serum (FBS) (v/v), L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES [N-(2-hydroxyethyl) piperazine-N'-2-ethanesulfonic acid 10 mM], non-essential amino acids and bovine insulin (1 mg/mL) (maintenance
15 medium). Ten days prior to assay, MCF-7 cells were switched to maintenance medium supplemented with 10% dextran-coated charcoal stripped fetal bovine serum (DCC-FBS) assay medium in place of 10% FBS to deplete internal stores of steroids. MCF-7 cells were removed from maintenance flasks using cell
20 dissociation medium ($\text{Ca}^{+2}/\text{Mg}^{+2}$ free HBSS (phenol red-free) supplemented with 10 mM HEPES and 2 mM EDTA). Cells were washed twice with assay medium and adjusted to 80,000 cells/mL. Approximately 100 mL (8,000 cells) were added to flat-bottom microculture wells (Costar 3596) and incubated
25 at 37°C in a 5% CO_2 humidified incubator for 48 hours to allow for cell adherence and equilibration after transfer. Serial dilutions of drugs or DMSO as a diluent control were prepared in assay medium and 50 mL transferred to triplicate microcultures followed by 50 mL assay medium for a final
30 volume of 200 mL. After an additional 48 hours at 37°C in a 5% CO_2 humidified incubator, microcultures were pulsed with tritiated thymidine (1 mCi/well) for four hours. Cultures were terminated by freezing at -70°C for 4 hours followed by thawing and harvesting of microcultures using a Skatron

Semiautomatic Cell Harvester. Samples were counted by liquid scintillation using a Wallac BetaPlace b-counter. Relative to 17 β -estradiol's known effects on the proliferation of MCF-7, the representative compounds of the present invention demonstrated significantly less stimulatory activity. In most cases, no effect was observed at the highest concentrations tested, and in some cases an inhibitory effect was observed.

10 Administration and Formulation

For the majority of the methods of the present invention, compounds of formula I are administered continuously, from 1 to 3 times daily. However, cyclical therapy may especially be useful in the treatment of endometriosis or may be used acutely during painful attacks of the disease. In the case of restenosis, therapy may be limited to short (one to six months) intervals following medical procedures such as angioplasty.

The specific dose of a compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the state of being of the patient, and the pathological condition being treated. A typical daily dose will contain a nontoxic dosage level of from about 5 mg to about 600 mg/day of a compound of the present invention. Preferred daily doses generally will be from about 15 mg to about 100 mg/day.

The compounds of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal, the selection of which will be decided by the attending physician. These compounds preferably are formulated prior to administration. Thus, another aspect of the present

invention is a pharmaceutical composition comprising an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, optionally containing an effective amount of estrogen or progestin, and
5 a pharmaceutically acceptable carrier, diluent, or excipient. The total active ingredients in such formulations comprises from 0.1% to 99.9% by weight of the formulation.

Pharmaceutical formulations of the present invention
10 can be prepared by procedures known in the art using well known and readily available ingredients. For example, the compounds of formula I, with or without an estrogen or progestin compound, can be formulated with common excipients, diluents, or carriers, and formed into tablets,
15 capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose
20 and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary
25 ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethylene glycols.

The compounds also can be formulated as elixirs or
30 solutions for convenient oral administration or as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous, or intravenous routes. Additionally, the compounds are well suited for formulation as sustained-release dosage forms and the like. The

formulations can be so constituted that they release the active ingredient only or preferably in a particular physiological location, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.

The following formulation examples are illustrative only and are not intended to limit the scope of the present invention.

10

Formulations

In the formulations which follow, "active ingredient" means a compound of formula I, or a salt thereof.

Hard gelatin capsules are prepared using the following:

15

Formulation 1 Gelatin Capsules

Ingredient	Quantity (mg/capsule)
Active ingredient	0.1 - 1000
Starch, NF	0 - 650
Starch flowable powder	0 - 650
Silicone fluid 350 centistokes	0 - 15

The formulation above may be changed in compliance with the reasonable variations provided.

20

A tablet formulation is prepared using the ingredients below:

Formulation 2 Tablets

Ingredient	Quantity (mg/tablet)
Active ingredient	2.5 - 1000
Cellulose, microcrystalline	200 - 650
Silicon dioxide, fumed	10 - 650
Stearate acid	5 - 15

The components are blended and compressed to form tablets.

- 5 Alternatively, tablets each containing 2.5 mg - 1000 mg of active ingredient are made up as follows:

Formulation 3

Tablets

Ingredient	Quantity (mg/tablet)
Active ingredient	25 - 1000
Starch	45
Cellulose, microcrystalline	35
Polyvinylpyrrolidone	4
(as 10% solution in water)	
Sodium carboxymethyl cellulose	4.5
Magnesium stearate	0.5
Talc	1

10

- The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C-60°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
- 15
- 20

Suspensions each containing 0.1 mg - 1000 mg of medicament per 5 ml dose are made as follows:

Formulation 4Suspensions

Ingredient	Quantity (mg/5 ml)
Active ingredient	0.1 - 1000 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mg
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified water to	5 mL

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

10

An aerosol solution is prepared containing the following ingredients:

Formulation 5Aerosol

15

Ingredient	Quantity (% by weight)
Active ingredient	0.25
Ethanol	25.75
Propellant 22 (Chlorodifluoromethane)	70.00

The active ingredient is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to 30°C, and transferred to a filling device. The required amount is then fed to a stainless steel container and

20

diluted with the remaining propellant. The valve units are then fitted to the container.

Suppositories are prepared as follows:

5

Formulation 6

Suppositories

Ingredient	Quantity (mg/suppository)
Active ingredient	250
Saturated fatty acid glycerides	2,000

10 The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimal necessary heat. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

15 An intravenous formulation is prepared as follows:

Formulation 7

Intravenous Solution

Ingredient	Quantity
Active ingredient	50 mg
Isotonic saline	1,000 mL

20 The solution of the above ingredients is intravenously administered to a patient at a rate of about 1 mL per minute.

Formulation 8
Combination Capsule I

Ingredient	Quantity (mg/capsule)
Active ingredient	50
Premarin	1
Avicel pH 101	50
Starch 1500	117.50
Silicon Oil	2
Tween 80	0.5
Cab-O-Sil	0.25

Formulation 9
Combination Capsule II

5

Ingredient	Quantity (mg/capsule)
Active ingredient	50
Norethynodrel	5
Avicel pH 101	82.50
Starch 1500	90
Silicon Oil	2
Tween 80	0.50


Formulation 10
Combination Tablet

Ingredient	Quantity (mg/capsule)
Active ingredient	50
Premarin	1
Corn Starch NF	50
Povidone, K29-32	6
Avicel pH 101	41.50
Avicel pH 102	136.50
Crospovidone XL10	2.50
Magnesium Stearate	0.50
Cab-O-Sil	0.50

The preferred embodiment of the present invention is now fully described. Nothing in this description is intended to limit the scope or spirit of this invention.

We Claim:

1. A compound of formula I:



I

wherein:

R and R¹ are independently hydrogen, halo, hydroxy, or O-Pg;

10 R² is CHR³OR⁴, CO₂R⁵, CHOHCH₂NR⁶R⁷, or a heterocycle;

X is C=O, CH-OH, CH₂, O, or S;

Pg is independently at each occurrence a hydroxy protecting group;

R³ is hydrogen or CH₂OH;

15 R⁴ is hydrogen, C₁-C₆ alkyl, or COR⁸;

R⁵ is hydrogen, C₁-C₆ alkyl, or aryl;

R⁶ and R⁷ are independently at each occurrence hydrogen or C₁-C₆ alkyl, or R⁶ and R⁷ together with the nitrogen to which they are attached form a 3,5-dimethylpiperidino, 3-methylpiperidino, pyrrolidino, piperidino, or a
20 hexamethyleneimino ring;

R⁸ is hydrogen, C₁-C₆ alkyl, or aryl;

or a pharmaceutically acceptable salt or solvate thereof.

25 2. A compound according to Claim 1 wherein X is C=O.

3. A compound according to Claim 2 wherein R² is CHR³OR⁴, R³ is hydrogen, and R⁴ is hydrogen or C₁-C₄ alkyl.

4. A compound according to Claim 3 wherein R and R¹ are independently hydroxy or O-Pg and Pg is independently at each occurrence C₁-C₄ alkyl or aryl.

5 5. A compound according to Claim 4 wherein Pg is methyl, ethyl, t-butyl, phenyl, or benzyl.

6. A compound according to Claim 4 wherein R and R¹ are both hydroxy.

10

7. A compound according to Claim 2 wherein R² is CHR³OR⁴, R³ is hydrogen, R⁴ is COR⁸, R⁸ is hydrogen, C₁-C₆ alkyl, or aryl, and aryl is a phenyl or substituted phenyl group.

15

8. A compound according to Claim 7 wherein R and R¹ are independently hydroxy or O-Pg and Pg is independently at each occurrence C₁-C₄ alkyl or aryl.

20

9. A compound according to Claim 8 wherein Pg is methyl, ethyl, t-butyl, phenyl, or benzyl.

10. A compound according to Claim 8 wherein R and R¹ are both hydroxy.

25

11. A compound according to Claim 2 wherein R² is CO²R⁵ and R⁵ is hydrogen or C₁-C₄ alkyl.

12. A compound according to Claim 11 wherein R and R¹ are independently hydroxy or O-Pg and Pg is independently at each occurrence C₁-C₄ alkyl or aryl.

30

13. A compound according to Claim 12 wherein Pg is methyl, ethyl, t-butyl, phenyl, or benzyl.

14. A compound according to Claim 12 wherein R and R¹ are both hydroxy.

5 15. A compound according to Claim 2 wherein R² is
CHOHCH₂NR⁶R⁷ and R⁶ and R⁷ are independently at each
occurrence hydrogen or C₁-C₆ alkyl or R⁶ and R⁷ together with
the nitrogen to which they are attached form a 3,5-
dimethylpiperidino, 3-methylpiperidino, pyrrolidino, or
10 piperidino ring.

16. A compound according to Claim 15 wherein R and R¹
are independently hydroxy or O-Pg and Pg is independently at
each occurrence C₁-C₄ alkyl or aryl.

15

17. A compound according to Claim 16 wherein Pg is
methyl, ethyl, t-butyl, phenyl, or benzyl.

18. A compound according to Claim 16 wherein R and R¹
20 are both hydroxy.

19. A compound according to Claim 2 wherein R² is a
heterocycle where that heterocycle is a 3, 4, 5, or 6
membered saturated, partially unsaturated, or aromatic
25 optionally substituted ring, which contains 1 or 2 oxygen
atoms.

20. A compound according to Claim 19 wherein R and R¹
are independently hydroxy or O-Pg and Pg is independently at
30 each occurrence C₁-C₄ alkyl or aryl.

21. A compound according to Claim 20 wherein Pg is
methyl, ethyl, t-butyl, phenyl, or benzyl.

22. A compound according to Claim 20 wherein R and R¹ are both hydroxy.

23. A compound according to Claim 2 which is selected
5 from the group consisting of: [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [(4-t-Butoxyethoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [(4-Hydroxyethoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [(4-Hydroxyethoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [4-(Ethoxyethoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-(Ethoxyethoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [4-Carbomethoxymethoxyphenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-Carbomethoxymethoxyphenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-Carboxymethoxyphenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [4-(Tetrahydropyran-2-yl)methoxyphenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-(Tetrahydropyran-2-yl)methoxyphenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [4-([Tetrahydrofuran-2-yl]methoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-([Tetrahydrofuran-2-yl]methoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl] [4-([2,2-Dimethyl-1,3-dioxolan-3-yl]methoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl] [4-(2,3-Dihydroxypropoxy)phenyl]methanone; (R)-[6-Methoxy-2-(4-

10
15
20
25
30

- Methoxyphenyl)benzo[b]thiophen-3-yl][4-([2,2-Dimethyl-1,3-dioxolan-3-yl]methoxy)phenyl]methanone; (R)-[6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2,3-Dihydroxypropoxy)phenyl]methanone; [6-Methoxy-2-(4-
- 5 Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Cyclohexanoyloxyethoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(Cyclohexanoyloxyethoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-
- 10 (Benzoyloxyethoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(Benzoyloxyethoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Acetoxymethoxy)phenyl]methanone; [6-Hydroxy-2-(4-
- 15 Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(Acetoxymethoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(Trimethylacetoxymethoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-
- 20 (Trimethylacetoxymethoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][O-Epihydrin)-4-Hydroxyphenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Butylaminopropoxy)phenyl]methanone; [6-Methoxy-2-(4-
- 25 Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Pyrrolidinylpropoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Pyrrolidinylpropoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-
- 30 Piperidinypropoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Piperidinypropoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-

Isopropylamino]propoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Isopropylamino]propoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(3-[2-Hydroxy-(3a, 5b)-3,5-Dimethylpiperidinyl]propoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[(3a, 5a)-3,5-Dimethylpiperidinyl]propoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[(3a, 5b)-3,5-Dimethylpiperidinyl]propoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[(3a, 5a)-3,5-Dimethylpiperidinyl]propoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[3-Methylpiperidinyl]propoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-[3-Methylpiperidinyl]propoxy)phenyl]methanone; [6-Methoxy-2-(4-Methoxyphenyl)benzo[b]thiophen-3-yl][4-(2-Methoxy-3-Hexylaminopropoxy)phenyl]methanone; [6-Hydroxy-2-(4-Hydroxyphenyl)benzo[b]thiophen-3-yl][4-(2-Hydroxy-3-Pentylaminopropoxy)phenyl]methanone; or a pharmaceutically acceptable salt or solvate thereof.


24. A pharmaceutical formulation comprising a compound of Claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.

25. A formulation according to Claim 24 wherein said compound of formula I is a compound wherein X is C=O.

30

26. A method for treating the symptoms of postmenopausal syndrome which comprises administering to a woman in need of such treatment an effective amount of a compound of formula I:

64



I

5

wherein:

R and R¹ are independently hydrogen, halo, hydroxy, or O-Pg;

R² is CHR³OR⁴, CO₂R⁵, CHOCH₂NR⁶R⁷, or a heterocycle;

10 X is C=O, CH-OH, CH₂, O, or S;

Pg is independently at each occurrence a hydroxy protecting group;

R³ is hydrogen or CH₂OH;

R⁴ is hydrogen, C₁-C₆ alkyl, or COR⁸;

15 R⁵ is hydrogen, C₁-C₆ alkyl, or aryl;

R⁶ and R⁷ are independently at each occurrence hydrogen or C₁-C₆ alkyl, or R⁶ and R⁷ together with the nitrogen to which they are attached form a 3,5-dimethylpiperidino, 3-methylpiperidino, pyrrolidino, piperidino, or a
20 hexamethyleneimino ring;

R⁸ is hydrogen, C₁-C₆ alkyl, or aryl; or
a pharmaceutically acceptable salt or solvate thereof.

27. A method according to Claim 26 wherein said
25 formula I compound is a compound wherein X is C=O.

28. A method according to either Claim 26 or Claim 27 wherein the postmenopausal syndrome pathological condition is osteoporosis.

30

29. A method according to either Claim 26 or Claim 27 wherein the postmenopausal syndrome pathological condition is related to a cardiovascular disease.

- 5 30. A method according to either Claim 26 or Claim 27 wherein said postmenopausal syndrome is estrogen related breast cancer.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16327

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 549/51, 54, 55, 57, 58, 59; 548/570, 571, 572; 546/202; 540/596; 514/443, 422, 324, 211

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE: structure searched

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	US 4,133,814 A (JONES et al.) 09 January 1979, col.2, line 38, cols. 33-34, lines 10-20.	1-6, 24-25
A, P	US 5,688,796 A (CULLINAN et al.) 18 November 1997, see abstract.	1-30
A,P	US 5,760,030 A (BRYANT et al.) 02 June 1998, col.4, lines 45-65.	1-30

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 OCTOBER 1998

Date of mailing of the international search report

27 OCT 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DEBORAH LAMBKIN

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/16327

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):C07D 333/52, 333/64, 207/04, 409/00, 405/00; A61K 31/38, 31/40, 31/445, 31/55

A. CLASSIFICATION OF SUBJECT MATTER:

US CL : 549/51, 54, 55, 57, 58, 59; 548/570, 571, 572; 546/202; 540/596; 514/443, 422, 324, 211